Loading company…
Synvida develops drugs for coagulation and fibrosis-related diseases.
Founded in Shanghai in 2021, Synvida is a biopharmaceutical company focused on drug research and development in coagulation and fibrosis. Its programs address pulmonary fibrosis, thrombocytopenia, hemophilia and thrombotic diseases, and it has developed the EMPRESS system to build synthetic bacteriophage and yeast libraries. In January 2024, it raised approximately CNY 200 million in Series A funding to advance clinical and preclinical research. Founder Junling Liu is vice chairman of the Society of Vascular Medicine - Chinese Association of Pathophysiology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in